Eliem delays a depression trial, indefinitely postpones another after blaming CMC issues for low drug exposure
In the drug R&D world, plans are not set in stone, as Eliem Therapeutics exhibited Monday with shifts to its depression strategy.
The Seattle-UK biotech originally wanted to start two mid-stage depression trials this year but will have to delay one — in major depressive disorder — until next year and indefinitely postpone the other in perimenopausal depression. Back in April, Eliem delayed the launches of both Phase IIa trials because the biotech was curious as to why the exposure was lower than expected in a Phase Ib study, which tried to prove out the concepts of ETX-155 in photosensitive epilepsy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.